Displaying drugs 14726 - 14750 of 15841 in total
XMMME-001-DTPA 111 Indium
Investigational
APC8020
Investigational
Vadacabtagene leraleucel
Investigational
GALE-301
GALE-301 is an investigational cancer immunotherapy. It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]
Investigational
Matched Description: … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune …
MV-NB-02
Investigational
TPIV 200
TPIV 200 is a vaccine consisting of proteins from the folate receptor alpha mixed with Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Investigational
Falimarev
Investigational
Indium In-111 altumomab pentetate
Investigational
MGN-4893
MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.
Investigational
TNT-1
Investigational
BB 21217
BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as idecabtagene vicleucel (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for memory-like T cells.
Investigational
MVR-T3011
MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.
Investigational
Matched Description: … Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and …
Vixtimotamab
Investigational
Belagenpumatucel-L (SK-LU-1)
Investigational
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
AAV-AQP1
Investigational
Deoxynucleogene ancparvovec
Investigational
AML-2-23
Investigational
Erfonrilimab
Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).
Investigational
Matched Description: … a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and …
Albumin-stabilized nanoparticle (130 nm)
Investigational
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
LP-2307
LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Nanrilkefusp alfa
Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).
Investigational
Matched Description: … Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity …
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
Matched Description: … encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and …
Displaying drugs 14726 - 14750 of 15841 in total